Latest Posts › AMP v Myriad

Share:

USPTO Outlines Changes to Myriad-Mayo Guidance at BIO Symposium

Last Friday, at the Biotechnology Industry Organization (BIO) IP & Diagnostics Symposium in Alexandria, VA, the U.S. Patent and Trademark Office provided additional information regarding changes that the Office plans to make...more

10/1/2014 - AMP v Myriad Guidance Update Mayo v. Prometheus Myriad-Mayo Patent-Eligible Subject Matter Professional Conferences USPTO

USPTO Expected to Issue Revised Myriad-Mayo Guidance in October

During a session at today's biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting, the U.S. Patent and Trademark Office provided an update on the status of the Myriad-Mayo Guidance. ...more

9/18/2014 - AMP v Myriad Mayo v. Prometheus Myriad Myriad-Mayo Patents USPTO

Examination of Myriad-Mayo Guidance Comments -- AUTM, COGR, AAU, and APLU

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

8/22/2014 - AMP v Myriad Mayo v. Prometheus Patent Infringement Patent Litigation Patents SCOTUS USPTO

USPTO Holds Forum on Subject Matter Eligibility -- Part IV

On May 9, the U.S. Patent and Trademark Office held a four-hour long forum to receive public feedback on the Myriad-Mayo Guidance, which was issued by the Office on March 4. According to the Office's Guidance webpage, the...more

7/10/2014 - AMP v Myriad Mayo v. Prometheus Patent-Eligible Subject Matter Patents SCOTUS USPTO

USPTO Holds Forum on Subject Matter Eligibility -- Part III

Last Friday, the U.S. Patent and Trademark Office held a four-hour long forum to receive public feedback on the Myriad-Mayo Guidance, which was issued by the Office on March 4. According to the Office's Guidance webpage, the...more

5/16/2014 - AMP v Myriad Mayo v. Prometheus Patent Applications Patent-Eligible Subject Matter Patents SCOTUS USPTO

USPTO Issues Guidance for Analyzing Subject Matter Eligibility of Claims Reciting Laws of Nature/Natural Principles, Natural...

Earlier today, in a memorandum issued to the Patent Examining Corps by Deputy Commissioner for Patent Examination Policy Andrew Hirshfeld, the U.S. Patent and Trademark Office implemented a new procedure for determining the...more

3/5/2014 - AMP v Myriad Mayo v. Prometheus Patent-Eligible Subject Matter SCOTUS USPTO

More Q&A from Webinar on Top Patent Law Stories of 2013

On Tuesday, we presented a live webinar on the "Top Patent Law Stories of 2013." The webinar covered ten of the fourteen stories that made it onto Patent Docs seventh annual list of top biotech/pharma patent stories. Posts...more

1/24/2014 - 23andMe America Invents Act AMP v Myriad Biotechnology Bowman v Monsanto FTC v Actavis Innovation Act Life Sciences Monsanto Myriad Patent Infringement Patent Litigation Patent Reform Patent Trolls Patents Pharmaceutical SCOTUS

Top Three Stories of 2013

Reflecting upon the events of the past twelve months, Patent Docs presents its seventh annual list of top biotech/pharma patent stories. For 2013, we identified fourteen stories that were covered on Patent Docs last year...more

1/6/2014 - America Invents Act AMP v Myriad Biotechnology Bowman v Monsanto DNA First-to-File First-to-Invent Genetic Materials Genetically Engineered Seed Human Genes Inventors Monsanto Patent Infringement Patent Litigation Patent Reform Patents Pharmaceutical SCOTUS

Amici Submit Brief in Support of Ambry Genetics and Gene by Gene

Last week, the American Civil Liberties Union (ACLU), ACLU of Utah Foundation, Inc., Public Patent Foundation (PUBPAT), Association for Molecular Pathology (AMP), Breast Cancer Action, and AARP submitted an amici curiae brief...more

8/28/2013 - ACLU Ambry AMP v Myriad Infringement Myriad Patents SCOTUS

Consumer Watchdog Argues That WARF Stem Cell Patent Is Invalid under ยง 101

Last month, Consumer Watchdog filed its opening brief in an appeal of a Board decision affirming the patentability of U.S. Patent No. 7,029,913, arguing that the claims of the '913 patent are invalid because they cover...more

8/2/2013 - AMP v Myriad DNA Inter Partes Review Proceedings Obviousness Patent-Eligible Subject Matter Patents Stem cells

Senator Leahy Urges NIH to Use March-In Rights on Myriad BRCA Test

On Friday, Sen. Patrick Leahy (D-VT) sent a letter to Dr. Francis Collins, the Director of the National Institutes of Health (NIH), "to urge [the Director] to consider using march-in rights under the Bayh-Dole Act to ensure...more

7/18/2013 - AMP v Myriad Bayh-Dole Act BRCA DNA March-in Myriad NIH Patents USPTO

Consortium Launches Public Database of BRCA Data

On June 13, the Genetic Alliance announced the launch of an initiative to fill the public information gap caused by the lack of available genetic information for the BRCA1 and BRCA2 genes. ...more

7/5/2013 - AMP v Myriad Biotechnology BRCA DNA Genetic Materials Genetic Services Genetic Testing Patents Pharmaceutical

Reaction to Supreme Court's Decision in AMP v. Myriad

It has been just over two weeks since the Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., holding that a naturally occurring DNA segment is a product of nature and not patent...more

7/2/2013 - ACLU AIPLA AMP v Myriad DNA Myriad Patent-Eligible Subject Matter Patents Product of Nature Doctrine

Supreme Court Issues Decision in AMP v. Myriad -- Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

In a much anticipated decision, the Supreme Court issued its opinion this morning in Association for Molecular Pathology v. Myriad Genetics, Inc. In an opinion by Justice Thomas, joined by Chief Justice Roberts, Justices...more

6/14/2013 - AMP v Myriad Biotechnology DNA Human Genes Myriad Patent-Eligible Subject Matter Patents SCOTUS

USPTO Issues Memo on AMP v. Myriad to Examining Corps

On the same day that the Supreme Court handed down its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Patent and Trademark Office issued a one-page memorandum to its Patent Examining Corps...more

6/14/2013 - AMP v Myriad DNA Human Genes Myriad Patent-Eligible Subject Matter Patents SCOTUS USPTO

IPO Files Amicus Brief in Support of Respondents in AMP v. Myriad Genetics

In an amicus brief filed last week in support of respondents Myriad Genetics, Inc. et al., the Intellectual Property Owners Association (IPO) asked the Supreme Court to affirm the Federal Circuit's decision in Association for...more

3/20/2013 - AMP v Myriad Human Genes Intellectual Property Owners Association Patent-Eligible Subject Matter Patents SCOTUS

16 Results
|
View per page
Page: of 1